• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The selection of immune checkpoint inhibitors of programmed cell death (anti-PD-1) and its ligand (anti-PD-L1) makes matters more challenges for clinical practice.

作者信息

Wang Peng-Hui, Yang Szu-Ting, Liu Chia-Hao

机构信息

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Female Cancer Foundation, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

出版信息

Taiwan J Obstet Gynecol. 2024 Jul;63(4):448-450. doi: 10.1016/j.tjog.2024.05.004.

DOI:10.1016/j.tjog.2024.05.004
PMID:39004469
Abstract
摘要

相似文献

1
The selection of immune checkpoint inhibitors of programmed cell death (anti-PD-1) and its ligand (anti-PD-L1) makes matters more challenges for clinical practice.程序性细胞死亡免疫检查点抑制剂（抗PD-1）及其配体（抗PD-L1）的选择给临床实践带来了更多挑战。
Taiwan J Obstet Gynecol. 2024 Jul;63(4):448-450. doi: 10.1016/j.tjog.2024.05.004.
2
The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.程序性死亡受体-1与程序性死亡配体1疗法在晚期非小细胞肺癌中的相对和绝对获益：一项系统评价与荟萃分析。
Int Immunopharmacol. 2020 Oct;87:106852. doi: 10.1016/j.intimp.2020.106852. Epub 2020 Aug 3.
3
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.免疫检查点抑制剂（程序性细胞死亡蛋白 1 与程序性细胞死亡配体 1）在癌症患者中的应用：系统评价和荟萃分析。
JAMA Oncol. 2020 Mar 1;6(3):375-384. doi: 10.1001/jamaoncol.2019.5367.
4
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.针对程序性死亡 1 和程序性死亡配体 1 的免疫检查点治疗的生物标志物。
Biomed Pharmacother. 2020 Oct;130:110621. doi: 10.1016/j.biopha.2020.110621. Epub 2020 Sep 2.
5
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.程序性细胞死亡蛋白 1 与程序性细胞死亡配体 1 抑制剂在转移性肾细胞癌中的肿瘤学和毒性结局差异：系统评价和荟萃分析。
Cancer Treat Rev. 2021 Sep;99:102242. doi: 10.1016/j.ctrv.2021.102242. Epub 2021 Jun 12.
6
Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.程序性细胞死亡配体 1 表达在接受程序性细胞死亡蛋白 1/程序性细胞死亡配体 1 抑制剂治疗的头颈部癌症中的预后作用：基于临床试验的荟萃分析。
J Cancer Res Ther. 2021 Jul;17(3):676-687. doi: 10.4103/jcrt.JCRT_1606_20.
7
The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.PD-1 和 PD-L1 检查点信号抑制在乳腺癌免疫治疗中的最新进展。
Eur J Pharmacol. 2021 Mar 15;895:173867. doi: 10.1016/j.ejphar.2021.173867. Epub 2021 Jan 15.
8
[Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].[使用PD-1和PD-L1抑制剂治疗前列腺癌的免疫疗法]
Zhonghua Nan Ke Xue. 2020 Nov;26(10):944-948.
9
Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.抗 PD-1/PD-L1 治疗联合放疗的潜在问题和未解决问题。
Tumori. 2021 Aug;107(4):282-291. doi: 10.1177/0300891620940382. Epub 2020 Jul 31.
10
Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.癌症免疫疗法中的免疫检查点阻断：PD-1/PD-L1 抑制剂的作用机制、临床疗效和安全性特征。
Arch Immunol Ther Exp (Warsz). 2020 Nov 13;68(6):36. doi: 10.1007/s00005-020-00601-6.

引用本文的文献

1
3D Conformal Radiotherapy Versus the Conventional Box Technique for Cervical Cancer: A Dosimetric Observational Study.宫颈癌的三维适形放疗与传统方形野技术：一项剂量学观察性研究
Cureus. 2025 Aug 11;17(8):e89799. doi: 10.7759/cureus.89799. eCollection 2025 Aug.